Merck & Stock (MRK)

XNYS Sideways Alert Compare

Health Care · Fundamental analysis and chart analysis

Merck &'s revenue has grown by 6.3% a year over the last 5 years – slower than the median of the Health Care sector (+8.5%). The net margin in the last fiscal year was 28.1%, the sector median 13.9%. The 52-week high is 17.3% away (close of Nov 20, 2026). Most recently detected chart pattern: Warning pattern Double top on the 4-hour chart, detected on Nov 18, 2026, 15:30.

· How we analyze

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

3 strengths · 1 weakness · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 7 of 7 criteria with data met · 1 without data
  • Growth 5 of 6 criteria with data met · 1 without data
  • Dividend 7 of 7 criteria with data met
  • Financial strength 5 of 6 criteria with data met
Chart position above – position relative to the 200-day line

Strengths well above the threshold

  • Net margin 28.1% Threshold: above 10% · Distance +18.1 pp · Sector median 12.9% (63 stocks) · Fiscal year to Dec 31, 2025
  • Return on equity 34.7% Threshold: above 15% · Distance +19.7 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 31, 2025
  • Free cash flow margin 19.0% Threshold: above 10% · Distance +9.0 pp · Sector median 14.5% (61 stocks) · Fiscal year to Dec 31, 2025

Weaknesses well below the threshold

  • Piotroski F-Score 4 of 9 Threshold: at least 7 · Distance −3 points · Sector median 6 of 9 (47 stocks) · Fiscal year to Dec 31, 2025

On the radar

  • Position relative to the 200-day line: above (as of Nov 20, 2026)

What we do not know

  • Data missing: 2 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 31, 2025).
    • Operating margin above 15%
    • Over 10 years, revenue grew by more than 5% per year

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Merck & Co. is a major US pharmaceutical company, known as MSD outside North America. Its main drug is the cancer medicine Keytruda; it also makes vaccines such as Gardasil and animal health products. It is not related to the German Merck from Darmstadt. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Rahway, USA

According to the company, Merck & Co. is a global healthcare company with the segments Pharmaceutical and Animal Health. The pharmaceutical segment comprises human medicines and vaccines, including Keytruda and the Gardasil vaccine against certain papillomaviruses. The company supplies medicines mainly to wholesalers and retailers, hospitals, government agencies and managed care organizations, and vaccines mainly to physicians, distributors and government bodies. The Animal Health segment markets veterinary medicines and vaccines, for example Bravecto for parasite control and the antibiotic Nuflor for cattle and pigs. Customers are veterinarians, distributors, livestock producers, farmers and pet owners; in addition, there are digital products for identifying and monitoring animals.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

What the methods say about Merck &

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +0.7%
  • 7 days −9.5%
  • 30 days −10.8%
  • 1 year +40.8%
Day range (last trading day)
−0.5%Price at 15% of the range+2.6%
52-week range
−28.7%Price at 62% of the range+17.3%
Distance from the all-time high
−14.8%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Structure unclear or broken

    Price below the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 below the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles mixed
    • Close below the SMA 200
    • EMA 20 below the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Candle from Nov 20, 2026, 19:30

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran weaker than the S&P 500 and weaker than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
weaker
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
weaker
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX below 20 – hardly any trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
  • Volume elevated Volume on the last trading day at least 1.5 times the average of up to 50 trading days before – from 1.5x elevated.
  • Volatility normal Typical daily range (ATR 14) between 2 and 4% of the price – normal.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran weaker.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 7 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
7 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
7 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 5 of 10 years
  • February: higher in 4 of 10 years
  • March: higher in 7 of 10 years
  • April: higher in 4 of 10 years
  • May: higher in 7 of 10 years
  • June: higher in 6 of 10 years
  • July: higher in 3 of 10 years
  • August: higher in 7 of 10 years
  • September: higher in 3 of 10 years
  • October: higher in 6 of 10 years
  • November (current month): higher in 7 of 10 years
  • December: higher in 7 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January5 of 10
February4 of 10
March7 of 10
April4 of 10
May7 of 10
June6 of 10
July3 of 10
August7 of 10
September3 of 10
October6 of 10
November ●7 of 10
December7 of 10

Through October 2026 (last completed month) · from our daily candles

Opportunity at a glance Merck &

What does this mean? The card sums up chart patterns, potential to target, risk to stop and supports of Merck & on the 4H, daily and weekly charts – every figure with its timeframe.

Potential to target 1hidden 4-hour or daily chart
Risk to stop
hidden
Reward/risk
hidden

Remaining potential: moved since detection and still open to target 1 – each in % with timeframe.

Trend 4H mixed 1D mixed 1W mixed

In favour 1 · Against 0 Points without chart-pattern detail – you see every point with figure and date with a free account

You see all figures, supports, for and against, and similar stocks with a free account. Create a free account

Fundamental analysis

Merck & Co. · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 24, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.8%
dividend per share, average per year
Coverage by free cash flow
1.5x
covered from 1.0x

For you first Valuation

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 6
criteria with data met
Revenue per year (5 y)
+6.3%
EPS per year (5 y)
+21.2%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
7 of 7
criteria with data met
Net margin
28.1%
Cash flow ÷ profit
0.90x
backed from 1.0 · 3 years: 1.42x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
mixed
daily candles
mixed
4-hour candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 7 of 7 met · 1 without data

  • met: Gross margin above 40% 74.8%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 28.1%
  • met: Return on equity above 15% 34.7%
  • met: Free cash flow margin above 10% 19.0%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 38.4%
Gross margin

74.8% Fiscal year 2025

Rank 88 of 100: higher than 88% of 370 peers (All). strong.

Rank 85 of 100: higher than 85% of 49 peers (Sector). strong.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Net margin

28.1% Fiscal year 2025

Rank 88 of 100: higher than 88% of 584 peers (All). strong.

Rank 85 of 100: higher than 85% of 63 peers (Sector). strong.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

34.7% Fiscal year 2025

Rank 86 of 100: higher than 86% of 544 peers (All). strong.

Rank 88 of 100: higher than 88% of 54 peers (Sector). strong.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

13.3% Fiscal year 2025 (total assets at year end)

Rank 85 of 100: higher than 85% of 594 peers (All). strong.

Rank 82 of 100: higher than 82% of 63 peers (Sector). strong.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

38.4% Fiscal year 2025

Rank 52 of 100: higher than 52% of 595 peers (All). medium.

Rank 39 of 100: higher than 39% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

19.0% Fiscal year 2025

Rank 74 of 100: higher than 74% of 465 peers (All). strong.

Rank 68 of 100: higher than 68% of 61 peers (Sector). strong.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

12.4B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year +3.1%
  • met: Over 5 years, revenue grew by more than 5% per year +6.3%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • met: Over 3 years, EPS grew by more than 5% per year +8.4%
  • met: Over 5 years, EPS grew by more than 5% per year +21.2%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +1.3%
Revenue growth 3 years

+3.1% per year

Rank 35 of 100: higher than 35% of 578 peers (All). medium.

Rank 41 of 100: higher than 41% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+6.3% per year

Rank 36 of 100: higher than 36% of 549 peers (All). medium.

Rank 38 of 100: higher than 38% of 60 peers (Sector). medium.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

EPS growth 3 years

+8.4% per year

Rank 51 of 100: higher than 51% of 437 peers (All). medium.

Rank 58 of 100: higher than 58% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+21.2% per year

Rank 76 of 100: higher than 76% of 399 peers (All). strong.

Rank 84 of 100: higher than 84% of 47 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+16.7% per year

Rank 80 of 100: higher than 80% of 375 peers (All). strong.

Rank 79 of 100: higher than 79% of 46 peers (Sector). strong.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 3.28 USD
  • met: Payout ratio at most 60% of earnings 45%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +5.8%
  • met: Free cash flow per share covers the dividend 1.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 59% of free cash flow
Payout ratio

45% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+5.8% per year

Rank 38 of 100: higher than 38% of 321 peers (All). medium.

Rank 37 of 100: higher than 37% of 31 peers (Sector). medium.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

1.5x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 4 of 9
  • met: Long-term debt no higher than equity 0.89
  • met: Current assets cover current liabilities 1.54
  • met: Positive equity 52.6B USD
  • met: In 5 years, share count up by at most 5% −1.3%
  • met: Free cash flow positive in the last fiscal year 12.4B USD
Piotroski F-Score

4 of 9 Fiscal year 2025

Rank 8 of 100: higher than 8% of 310 peers (All). weak.

Rank 5 of 100: higher than 5% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.89 at fiscal year end

Rank 36 of 100: lower than 36% of 486 peers (All). medium.

Rank 21 of 100: lower than 21% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.54 at fiscal year end

Rank 58 of 100: higher than 58% of 513 peers (All). medium.

Rank 45 of 100: higher than 45% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−1.3% in 5 years

Rank 43 of 100: lower than 43% of 507 peers (All). medium.

Rank 35 of 100: lower than 35% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • not met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+6.3% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+20.9% per year), at least as fast as the sector median; per share +21.2% per year.
  • Light green: Net margin 28.1%, above the sector median (13.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 39.8B USD · Net income 3.9B USD · Net margin 9.8%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 40.1B USD · Net income 2.4B USD · Net margin 6.0%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 42.3B USD · Net income 6.2B USD · Net margin 14.7%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 46.8B USD · Net income 9.8B USD · Net margin 21.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 48.0B USD · Net income 7.1B USD · Net margin 14.7%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 48.7B USD · Net income 13.0B USD · Net margin 26.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 59.3B USD · Net income 14.5B USD · Net margin 24.5%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 60.1B USD · Net income 365.0M USD · Net margin 0.6%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 64.2B USD · Net income 17.1B USD · Net margin 26.7%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.0B USD · Net income 18.3B USD · Net margin 28.1%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.0B USD · Net income 18.3B USD · Net margin 28.1%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +4.7% vs. the same quarter a year earlier; grown for 5 quarters in a row.

Revenue 12 months vs. prior 12
+4.9%
12 months: 67.4B USD · Fiscal year 2025: +1.3%
Net margin 12 months
3.6%
Fiscal year 2025: 28.1%
Free cash flow margin 12 months
21.9%
Fiscal year 2025: 19.0%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 65.0B USD + year to date to Sep 30, 2026 51.0B USD − same period a year earlier to Sep 30, 2025 48.6B USD = 67.4B USD
  • Net income: fiscal year to Dec 31, 2025 18.3B USD + year to date to Sep 30, 2026 −510.0M USD − same period a year earlier to Sep 30, 2025 15.3B USD = 2.5B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 16.5B USD + year to date to Sep 30, 2026 15.8B USD − same period a year earlier to Sep 30, 2025 13.6B USD = 18.7B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 4.1B USD + year to date to Sep 30, 2026 2.9B USD − same period a year earlier to Sep 30, 2025 3.1B USD = 4.0B USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 2618.1B+4.7%5.1B28.0%
Apr–Jun 2616.6B+5.1%−1.3B−8.0%
Jan–Mar 2616.3B+4.9%−4.2B−26.0%
Oct–Dec 25*16.4B+5.0%3.0B18.1%
Jul–Sep 2517.3B+3.7%5.8B33.5%
Apr–Jun 2515.8B−1.9%4.4B28.0%
Jan–Mar 2515.5B−1.6%5.1B32.7%
Oct–Dec 24*15.6B+6.8%3.7B24.0%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Cash from the business is slightly below profit; interest is well covered.

Cash flow ÷ profit
0.90x
backed from 1.0 · 3 years: 1.42x
Interest coverage
16.5x
well covered from 5 · EBIT, derived · 3 years: 12.4x
Tax rate
13.3%
for information only · 3 years: 16.6%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 16.5B USD ÷ group profit incl. minority interests 18.3B USD = 0.90x
  • EBIT, derived (profit before tax plus interest expense) 22.4B USD ÷ Interest expense 1.4B USD = 16.5x
  • Taxes 2.8B USD ÷ profit before tax 21.1B USD = 13.3%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20250.90x16.5x13.3%
20241.25x16.7x14.1%
2023over 10x2.6x80.0%
20221.31x18.1x11.7%
20211.00x18.2x11.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year; no year with lower revenue across 9 years with a prior-year figure.

Loss years
0 of 10
net income below zero
Years with lower revenue
0 of 9
revenue below the prior year
Net margin range
27.5 percentage points
from 0.6% to 28.1%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+1.3%28.1%
2024+6.7%26.7%
2023+1.4%0.6%
2022+21.7%24.5%
2021+1.5%26.8%
2020+2.5%14.7%
2019+10.7%21.0%
2018+5.4%14.7%
2017+0.8%6.0%
2016–9.8%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Since when has today’s status held?

Check status by fiscal year

Quality: 7 of 7 criteria in every annual report since 2024; changed from the prior year: Growth and Financial strength.

  • Quality 7 of 7 since FY 2024 · before that 5 of 7
  • Growth 5 of 6 since FY 2025 · before that 6 of 6
  • Dividend 7 of 7 since FY 2024 · before that 6 of 7
  • Financial strength 5 of 6 since FY 2025 · before that 6 of 6
More depth
Criteria met by fiscal year (met/with data)
Check20212022202320242025
Quality7/77/75/77/77/7
Growth4/66/64/66/65/6
Dividend7/77/76/77/77/7
Financial strength6/65/65/66/65/6

Fiscal year 2025 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).

Earlier years as of the filing date of their annual report: FY 2024 on Feb 25, 2025, FY 2023 on Feb 26, 2024, FY 2022 on Feb 24, 2023, FY 2021 on Feb 25, 2022.

Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.

As of annual reports 2021–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 74.8 USD gross profit and 28.1 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue65.0B USD100.0%
Gross profit48.6B USD74.8%
Cost of revenue16.4B USD25.2%
Net income18.3B USD28.1%
Research & development15.8B USD24.3%
Interest expense1.4B USD2.1%
Taxes2.8B USD4.3%
Remaining costs & other10.4B USD16.0%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 14.7% to 28.1%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 64.8% · Net margin 9.8%
  2. Fiscal year 2017: Gross margin 67.8% · Net margin 6.0%
  3. Fiscal year 2018: Gross margin 68.1% · Net margin 14.7%
  4. Fiscal year 2019: Gross margin 69.9% · Net margin 21.0%
  5. Fiscal year 2020: Gross margin 67.7% · Net margin 14.7%
  6. Fiscal year 2021: Gross margin 72.0% · Net margin 26.8%
  7. Fiscal year 2022: Gross margin 70.6% · Net margin 24.5%
  8. Fiscal year 2023: Gross margin 73.2% · Net margin 0.6%
  9. Fiscal year 2024: Gross margin 76.3% · Net margin 26.7%
  10. Fiscal year 2025: Gross margin 74.8% · Net margin 28.1%

Returns

Return on equity rose in 5 years from 27.9% to 34.7%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 9.8% · Return on assets 4.1%
  2. Fiscal year 2017: Return on equity 7.0% · Return on assets 2.7%
  3. Fiscal year 2018: Return on equity 23.3% · Return on assets 7.5%
  4. Fiscal year 2019: Return on equity 38.0% · Return on assets 11.7%
  5. Fiscal year 2020: Return on equity 27.9% · Return on assets 7.7%
  6. Fiscal year 2021: Return on equity 34.2% · Return on assets 12.3%
  7. Fiscal year 2022: Return on equity 31.6% · Return on assets 13.3%
  8. Fiscal year 2023: Return on equity 1.0% · Return on assets 0.3%
  9. Fiscal year 2024: Return on equity 37.0% · Return on assets 14.6%
  10. Fiscal year 2025: Return on equity 34.7% · Return on assets 13.3%

Equity and long-term debt

The equity ratio rose in 5 years from 27.6% to 38.4%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 40.1B USD · Long-term debt 24.3B USD
  2. Fiscal year 2017: Equity 34.3B USD · Long-term debt 21.4B USD
  3. Fiscal year 2018: Equity 26.7B USD · Long-term debt 19.8B USD
  4. Fiscal year 2019: Equity 25.9B USD · Long-term debt 22.7B USD
  5. Fiscal year 2020: Equity 25.3B USD · Long-term debt 25.4B USD
  6. Fiscal year 2021: Equity 38.2B USD · Long-term debt 30.7B USD
  7. Fiscal year 2022: Equity 46.0B USD · Long-term debt 28.7B USD
  8. Fiscal year 2023: Equity 37.6B USD · Long-term debt 33.7B USD
  9. Fiscal year 2024: Equity 46.3B USD · Long-term debt 34.5B USD
  10. Fiscal year 2025: Equity 52.6B USD · Long-term debt 46.8B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.02 to 1.54.

Current ratio
  1. Fiscal year 2016: Current ratio 1.78
  2. Fiscal year 2017: Current ratio 1.33
  3. Fiscal year 2018: Current ratio 1.17
  4. Fiscal year 2019: Current ratio 1.24
  5. Fiscal year 2020: Current ratio 1.02
  6. Fiscal year 2021: Current ratio 1.27
  7. Fiscal year 2022: Current ratio 1.47
  8. Fiscal year 2023: Current ratio 1.25
  9. Fiscal year 2024: Current ratio 1.36
  10. Fiscal year 2025: Current ratio 1.54

Cash flow

Free cash flow rose in 5 years from 5.6B USD to 12.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 10.4B USD · Capital expenditure 1.6B USD · Free cash flow 8.8B USD
  2. Fiscal year 2017: Operating cash flow 6.4B USD · Capital expenditure 1.9B USD · Free cash flow 4.6B USD
  3. Fiscal year 2018: Operating cash flow 10.9B USD · Capital expenditure 2.6B USD · Free cash flow 8.3B USD
  4. Fiscal year 2019: Operating cash flow 13.4B USD · Capital expenditure 3.5B USD · Free cash flow 10.0B USD
  5. Fiscal year 2020: Operating cash flow 10.3B USD · Capital expenditure 4.7B USD · Free cash flow 5.6B USD
  6. Fiscal year 2021: Operating cash flow 13.1B USD · Capital expenditure 4.4B USD · Free cash flow 8.7B USD
  7. Fiscal year 2022: Operating cash flow 19.1B USD · Capital expenditure 4.4B USD · Free cash flow 14.7B USD
  8. Fiscal year 2023: Operating cash flow 13.0B USD · Capital expenditure 3.9B USD · Free cash flow 9.1B USD
  9. Fiscal year 2024: Operating cash flow 21.5B USD · Capital expenditure 3.4B USD · Free cash flow 18.1B USD
  10. Fiscal year 2025: Operating cash flow 16.5B USD · Capital expenditure 4.1B USD · Free cash flow 12.4B USD

Share count

The share count fell in 5 years by 1.3% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 2.8B
  2. Fiscal year 2017: Diluted share count 2.7B
  3. Fiscal year 2018: Diluted share count 2.7B
  4. Fiscal year 2019: Diluted share count 2.6B
  5. Fiscal year 2020: Diluted share count 2.5B
  6. Fiscal year 2021: Diluted share count 2.5B
  7. Fiscal year 2022: Diluted share count 2.5B
  8. Fiscal year 2023: Diluted share count 2.5B
  9. Fiscal year 2024: Diluted share count 2.5B
  10. Fiscal year 2025: Diluted share count 2.5B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Dividend per share

The dividend per share rose in 5 years from 2.48 USD to 3.28 USD.

MRK USD per share
  1. Fiscal year 2016: MRK 1.85 USD
  2. Fiscal year 2017: MRK 1.89 USD
  3. Fiscal year 2018: MRK 1.99 USD
  4. Fiscal year 2019: MRK 2.26 USD
  5. Fiscal year 2020: MRK 2.48 USD
  6. Fiscal year 2021: MRK 2.64 USD
  7. Fiscal year 2022: MRK 2.80 USD
  8. Fiscal year 2023: MRK 2.96 USD
  9. Fiscal year 2024: MRK 3.12 USD
  10. Fiscal year 2025: MRK 3.28 USD

Payout ratio (earnings)

The payout ratio fell in 5 years from 89.2% to 45.1%.

MRK
  1. Fiscal year 2016: MRK 131.2%
  2. Fiscal year 2017: MRK 217.2%
  3. Fiscal year 2018: MRK 85.8%
  4. Fiscal year 2019: MRK 59.3%
  5. Fiscal year 2020: MRK 89.2%
  6. Fiscal year 2021: MRK 51.4%
  7. Fiscal year 2022: MRK 49.0%
  8. Fiscal year 2023: MRK not available
  9. Fiscal year 2024: MRK 46.3%
  10. Fiscal year 2025: MRK 45.1%

Payout ratio (free cash flow)

The payout ratio (free cash flow) fell in 5 years from 111.6% to 66.1%.

MRK
  1. Fiscal year 2016: MRK 58.5%
  2. Fiscal year 2017: MRK 113.3%
  3. Fiscal year 2018: MRK 62.3%
  4. Fiscal year 2019: MRK 57.1%
  5. Fiscal year 2020: MRK 111.6%
  6. Fiscal year 2021: MRK 76.2%
  7. Fiscal year 2022: MRK 47.7%
  8. Fiscal year 2023: MRK 81.4%
  9. Fiscal year 2024: MRK 43.3%
  10. Fiscal year 2025: MRK 66.1%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+5.8%
dividend per share, average per year
Coverage by free cash flow
1.5x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 2.48 USD → fiscal year 2025 3.28 USD = +5.8% per year
  • Free cash flow per share 4.93 USD ÷ dividend per share 3.28 USD = 1.5x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.28 USD · Fiscal year 2025
Dividend growth per year
3 y +5.4%5 y +5.8%10 y +6.1%
Payout ratio
of earnings 45% of free cash flow 66%
To shareholders (5 years)
45.7B USD 19% through repurchases
Share count over 5 years
−1.3% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 2.48 USD to 3.28 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.85 USD
  2. Fiscal year 2017: Dividend per share 1.89 USD
  3. Fiscal year 2018: Dividend per share 1.99 USD
  4. Fiscal year 2019: Dividend per share 2.26 USD
  5. Fiscal year 2020: Dividend per share 2.48 USD
  6. Fiscal year 2021: Dividend per share 2.64 USD
  7. Fiscal year 2022: Dividend per share 2.80 USD
  8. Fiscal year 2023: Dividend per share 2.96 USD
  9. Fiscal year 2024: Dividend per share 3.12 USD
  10. Fiscal year 2025: Dividend per share 3.28 USD

Payout ratios

The payout ratio fell in 5 years from 89.2% to 45.1%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2016: Payout ratio (earnings) 131.2% · Payout ratio (free cash flow) 58.5%
  2. Fiscal year 2017: Payout ratio (earnings) 217.2% · Payout ratio (free cash flow) 113.3%
  3. Fiscal year 2018: Payout ratio (earnings) 85.8% · Payout ratio (free cash flow) 62.3%
  4. Fiscal year 2019: Payout ratio (earnings) 59.3% · Payout ratio (free cash flow) 57.1%
  5. Fiscal year 2020: Payout ratio (earnings) 89.2% · Payout ratio (free cash flow) 111.6%
  6. Fiscal year 2021: Payout ratio (earnings) 51.4% · Payout ratio (free cash flow) 76.2%
  7. Fiscal year 2022: Payout ratio (earnings) 49.0% · Payout ratio (free cash flow) 47.7%
  8. Fiscal year 2023: Payout ratio (earnings) not available · Payout ratio (free cash flow) 81.4%
  9. Fiscal year 2024: Payout ratio (earnings) 46.3% · Payout ratio (free cash flow) 43.3%
  10. Fiscal year 2025: Payout ratio (earnings) 45.1% · Payout ratio (free cash flow) 66.1%

What goes back to shareholders

Over 5 years, 45.7B USD went back to shareholders, 19% of it through share repurchases. That is 72% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 5.1B USD · Share repurchases 3.4B USD · New shares issued (including employee plans) not available · Free cash flow 8.8B USD
  2. Fiscal year 2017: Dividends paid 5.2B USD · Share repurchases 4.0B USD · New shares issued (including employee plans) not available · Free cash flow 4.6B USD
  3. Fiscal year 2018: Dividends paid 5.2B USD · Share repurchases 9.1B USD · New shares issued (including employee plans) not available · Free cash flow 8.3B USD
  4. Fiscal year 2019: Dividends paid 5.7B USD · Share repurchases 4.8B USD · New shares issued (including employee plans) not available · Free cash flow 10.0B USD
  5. Fiscal year 2020: Dividends paid 6.2B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 5.6B USD
  6. Fiscal year 2021: Dividends paid 6.6B USD · Share repurchases 840.0M USD · New shares issued (including employee plans) not available · Free cash flow 8.7B USD
  7. Fiscal year 2022: Dividends paid 7.0B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 14.7B USD
  8. Fiscal year 2023: Dividends paid 7.4B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 9.1B USD
  9. Fiscal year 2024: Dividends paid 7.8B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 18.1B USD
  10. Fiscal year 2025: Dividends paid 8.2B USD · Share repurchases 5.1B USD · New shares issued (including employee plans) not available · Free cash flow 12.4B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Merck & Co. next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MRK, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. this stock 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
Median of the sector 26 symbols 44.4B USD +8.5%67.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector MRK next to LLY – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+6.3% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 6.3% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+20.9% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +21.2% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 20.9% per year on average – at least as fast as the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.1% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 28.08 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 14.7%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

1.11 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 1.11 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

45% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.45 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
65.0B USD
Revenue vs. prior year
+1.3%
Net income (FY)
18.3B USD
Net income vs. prior year
+6.6%
EPS (FY)
7.28 USD
Superinvestors holding
4 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Sep 30, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 65.0B18.3B 28.1% 7.28 3.28 45%
2024Dec 31, 2024 64.2B17.1B 26.7% 6.74 3.12 46%
2023Dec 31, 2023 60.1B365.0M 0.6% 0.14 2.96 2,114%
2022Dec 31, 2022 59.3B14.5B 24.5% 5.71 2.80 49%
2021Dec 31, 2021 48.7B13.0B 26.8% 5.14 2.64 51%
2020Dec 31, 2020 48.0B7.1B 14.7% 2.78 2.48 89%
2019Dec 31, 2019 46.8B9.8B 21.0% 3.81 2.26 59%
2018Dec 31, 2018 42.3B6.2B 14.7% 2.32 1.99 86%
2017Dec 31, 2017 40.1B2.4B 6.0% 0.87 1.89 217%
2016Dec 31, 2016 39.8B3.9B 9.8% 1.41 1.85 131%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 18.1B5.1B 28.0% 2.04 0.85 42%
Q2/26Jun 30, 2026 16.6B−1.3B −8.0% −0.54 0.85 –
Q1/26Mar 31, 2026 16.3B−4.2B −26.0% −1.72 0.85 –
Q4/25*Dec 31, 2025 16.4B3.0B 18.1% – 0.85 –
Q3/25Sep 30, 2025 17.3B5.8B 33.5% 2.32 0.81 35%
Q2/25Jun 30, 2025 15.8B4.4B 28.0% 1.76 0.81 46%
Q1/25Mar 31, 2025 15.5B5.1B 32.7% 2.01 0.81 40%
Q4/24*Dec 31, 2024 15.6B3.7B 24.0% – 0.81 –
Q3/24Sep 30, 2024 16.7B3.2B 19.0% 1.24 0.77 62%
Q2/24Jun 30, 2024 16.1B5.5B 33.9% 2.14 0.77 36%
Q1/24Mar 31, 2024 15.8B4.8B 30.2% 1.87 0.77 41%
Q4/23*Dec 31, 2023 14.6B−1.2B −8.4% – 0.77 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $8.6M1 person −$8.6M
6 months $00 people $38.6M5 people −$38.6M
12 months $00 people $79.3M10 people −$79.3M

Latest transactions

  • Nov 12, 2026 DeLuca Richard R. Officer Open-market sale 58,185 shares · $8.6M · SEC
  • Aug 13, 2026 Guindo Chirfi Officer Open-market sale 10,000 shares · $1.4M · SEC
  • Aug 12, 2026 Zachary Jennifer Officer Open-market sale 80,315 shares · $10.7M · SEC
  • Aug 12, 2026 DeLuca Richard R. Officer Open-market sale 600 shares · $79.2K · SEC
  • Aug 12, 2026 DeLuca Richard R. Officer Open-market sale 11,099 shares · $1.5M · SEC
  • Aug 11, 2026 DeLuca Richard R. Officer Open-market sale 5,427 shares · $718.3K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Merck & Co.?

All superinvestor portfolios

4 of 26 tracked superinvestors report a position.

Superinvestors with a position in Merck & Co., weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Paul Tudor Jones Tudor Investment Corp 0.3% new Q3 2026
Steve Cohen Point72 Asset Management 0.3% +196.1% increased Q3 2026
Bridgewater Associates < 0.1% +29.9% increased Q3 2026
Renaissance Technologies < 0.1% new Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score +15

Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+10
Price change 60 days-15

Volatility and trend strength

ADX 14 (trend strength)hardly any trend (below 20)
Price change 60 daysdown

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MRK yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MRK

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close